US20090308780A1 - Medicinal package - Google Patents

Medicinal package Download PDF

Info

Publication number
US20090308780A1
US20090308780A1 US12/311,252 US31125207A US2009308780A1 US 20090308780 A1 US20090308780 A1 US 20090308780A1 US 31125207 A US31125207 A US 31125207A US 2009308780 A1 US2009308780 A1 US 2009308780A1
Authority
US
United States
Prior art keywords
methyl
smells
package
oxo
chemical absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/311,252
Other languages
English (en)
Inventor
Koji Nonomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to US12/311,252 priority Critical patent/US20090308780A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NONOMURA, KOJI
Publication of US20090308780A1 publication Critical patent/US20090308780A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers

Definitions

  • the present invention relates to a medicinal package wherein unpleasant smells are reduced.
  • captopril which is an ACE inhibitor
  • fursultiamine which is a vitamin B1 deficiency remedy
  • rimatil which is an antirheumatic
  • L-cysteine which is a liver-function enhancer
  • olmesartan medoxomil an angiotensin II receptor antagonist
  • Methods for reducing unpleasant smells generally, include the decomposition method, the absorption method and the masking method.
  • the decomposition method which is a method wherein odorous materials are decomposed, includes decomposition by ozone, decomposition by a catalyst and decomposition by a chemical agent.
  • the absorption method which is a method wherein odorous materials are absorbed physically, includes absorption by synthetic zeolite, silica gel, silica-alumina or active carbon, or mixtures of more than two kinds thereof, and absorption to an electric field to which a high voltage is applied.
  • the masking method is a method that makes unpleasant smells less sensible using an aromatic and the like. From the perspective of application to medicinal preparation, it is normally used to reduce smells by making an absorptive removal of odorous materials by packing synthetic zeolite, silica gel, silica-alumina, or active carbon together in a bottle.
  • a synthetic zeolite, silica gel, silica-alumina, or an active carbon as well as a metallic oxide such as calcium oxide can be used as a desiccant. It is considered that the desiccation by a metallic oxide is caused by a chemical reaction of the metallic oxide with moisture.
  • the absorption of moisture or odorous materials to desiccants such as a synthetic zeolite, silica gel, silica-alumina, or an active carbon is a reversible reaction.
  • concentration level of moisture or smell in the package is under the equilibrium between a headspace in the package and desorption-absorption by the desiccant.
  • the inventor of the present invention dedicatedly researched to realize the efficient and continuous reduction of smell in medicinal preparations comprising compounds giving out unpleasant smells.
  • a chemical absorption-type desiccant such as a metallic oxide effectively reduced smells in a medicinal preparation, and have completed the present invention.
  • the present invention relates to
  • FIG. 1 shows the layer structure of a cold formable laminate for manufacturing blister base parts shown in FIG. 5 , corresponding to the section line II-II in FIG. 5 .
  • FIG. 2 shows the layered make-up of a lid film—that can be broken open by applying pressure—for the blister base parts according to FIG. 5 , along section line III-III in FIG. 5 .
  • FIG. 3 shows the layered make-up of a peelable lid film for blister base parts.
  • FIG. 4 shows a plan view of a blister base part, made by cold forming the laminate of FIG. 1 .
  • FIG. 5 shows a section through the blister base part of FIG. 4 along line I-I.
  • FIG. 6 shows a blister base part of FIG. 5 with sealed-on push through film of FIG. 2 or peelable lid film of FIG. 3 .
  • a chemical absorption-type desiccant used in the present invention may be any materials which can give drying effects by the chemical reaction with moisture, and it includes, for example, metallic oxide, such as an alkaline earth metallic oxide (e.g. calcium oxide (CaO) etc.), an alkaline earth metallic hydroxide (e.g. calcium hydroxide etc.), sulfate of an alkaline earth metal (e.g. magnesium sulfate etc.) and the like.
  • metallic oxide such as an alkaline earth metallic oxide (e.g. calcium oxide (CaO) etc.), an alkaline earth metallic hydroxide (e.g. calcium hydroxide etc.), sulfate of an alkaline earth metal (e.g. magnesium sulfate etc.) and the like.
  • the chemical absorption-type desiccant may be contained in the material composing the medicinal package, or placed in the internal space of the medicinal package.
  • the content of the chemical absorption-type desiccant in the material composing the medicinal package is 0.5 wt. % to 60 wt. %, preferably 5 wt. % to 50 wt. %, more preferably 10 wt. % to 40 wt. %.
  • the amount of the chemical absorption-type desiccant in the internal space of the medicinal package does not have any particular limit, so long as the amount is sufficient to remove the odorous material, that is, sufficient to suppress or reduce the smell.
  • the amount of the chemical absorption-type desiccant can vary depending on kind or shape of the desiccant, distance from the medicinal preparation capable of giving out smells, amount of the compound giving out smells, what the formulation is, volume of the space where the medicinal preparation and the desiccant are placed, amount of the existing or produced odorous material, preservation condition of the medicinal package.
  • the amount of the desiccant is about 50 mg to about 100 g, preferably about 300 mg to about 50 g, more preferably about 500 mg to about 20 g.
  • the packaging component storing a medicinal preparation that can give out smells
  • the packaging component is something which can store the medicinal preparation that can give out smells in an airtight space
  • the packaging component is not to be limited to something, but bottles such as a glass bottle, a plastic bottle and the like, packaging bags such as a plastic bag (including those deposited by aluminum, silicon dioxide (silica)), an aluminum laminated bag and the like, a strip package, a metal can and a composite thereof, and a blister package and the like can be used.
  • the bottle may be composed of uni-layer or multi-layer.
  • the bottle is molded from a resin integrated with a chemical absorption-type desiccant.
  • the outer layer is one having a high barrier property, and the layer containing a chemical absorption-type desiccant is formed by coating, lamination, or integration (e.g., mixing) of the chemical absorption-type desiccant into a resin.
  • the packaging component is a blister package
  • the chemical absorption-type desiccant is contained in the material composing the packaging component by inserting a resin integrated with the chemical absorption-type desiccant in the blister material resin.
  • outer layer is one having a high barrier property, and that a chemical absorption-type desiccant is contained in materials for the packaging component by being coated or laminated at the inside of the blister material resin, or by directly being integrated (e.g., mixed) with the blister material.
  • the packaging component is a packaging bag or a strip package
  • the chemical absorption-type desiccant is contained in the material composing the packaging component by inserting a resin integrated with a chemical absorption-type desiccant in the bag or strip packaging material resin.
  • outer layer is one having a high barrier property, and that a chemical absorption-type desiccant is contained in materials for the packaging component by being coated or laminated at the inside of the bag or strip packaging material resin, or by directly being integrated (e.g., mixed) with the material for the bag or strip package.
  • the medicinal preparation capable of giving out smells in the present invention can comprise compounds giving out smells themselves, or can comprise compounds giving out smells by their decomposition.
  • compounds giving out smells themselves or can comprise compounds giving out smells by their decomposition.
  • compounds giving out smells themselves or “compounds giving out smells by their decomposition”
  • compounds giving out smells will be collectively called “compounds giving out smells”.
  • the compounds giving out smells are, for example, compounds having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group (so-called a medoxomil group) within their molecules (for example, olmesartan medoxomil, compound A, compound B and the like).
  • the compounds having a medoxomil group within their molecules generate a low molecular weight compound, 2,3-butanedione (also called biacetyl or diacetyl), by having their medoxomil ester cleaved gradually, and 2,3-butanedione is considered to be a causative material of the peculiar smell.
  • the compound A is also represented as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1- ⁇ [2′-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl ⁇ -1H-benzimidazole-7-carboxylate.
  • the compound B is also represented as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-cyclopropyl-1- ⁇ [2′-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl ⁇ -1H-benzimidazole-7-carboxylate.
  • the compound A and the compound B can be manufactured by a method disclosed in the international publication No. 2005/080384 or 2006/107062, or by a method similar thereto.
  • the compounds giving out smells also may be pharmaceutically acceptable salts thereof.
  • salts with an inorganic base e.g. alkali metals such as sodium, potassium and the like, alkaline earth metals such as calcium, magnesium and the like, and transition metals such as zinc, iron, copper and the like
  • an organic base e.g.
  • organic amines such as trimethylamine, triethylamine, pyridine, picoline, tromethamine, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, t-butylamine, N,N′-dibenzylethylenediamine and the like, and basic amino acids such as arginine, lysine, ornithine and the like) can be used.
  • a basic functional group is included within the compound, for example, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, or salts with organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid and the like can be used.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like
  • organic acids such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid and the like
  • the medicinal preparations capable of giving out smells are, for example, solid preparations, which are appropriate for taking orally, such as tablets, capsules, pills and the like.
  • the solid preparations can be manufactured by a method known per se (e.g. a method written in general rules of medicine manufacture of the 14 th revision of Japanese Pharmacopoeia).
  • effective ingredients and diluents e.g. lactose, white sugar, glucose, starch, cornstarch, sucrose, microcrystalline cellulose, powdered licorice, mannitol, sorbitol, sodium bicarbonate, calcium phosphate, calcium sulfate and the like
  • disintegrating agents e.g.
  • amino acid, starch, cornstarch, calcium carbonate, carmellose sodium, crosscarmellose calcium, crosscarmellose sodium, low substituted hydroxypropyl cellulose, crospovidone, carboxymethyl starch sodium and the like) are added for mixing, bonding agents (e.g. hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, starch, gum arabic, tragacanth, carboxy methylcellulose, sodium alginate, pullulan, glycerol and the like) are added to make granules, and lubricants (e.g. magnesium stearate, calcium stearate, refined talc and the like) are added to make tablets.
  • bonding agents e.g. hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, starch, gum arabic, tragacanth, carboxy methylcellulose, sodium alginate, pullulan, g
  • Granules and fine granules are also granulated in an almost same way as that of making tablets, or nonpareil (Product name, spherical granules containing sucrose 75% (W/W) and cornstarch 25% (W/W)) is coated, while being sprayed with water or a solution of a bonding agent such as white sugar, hydroxypropyl cellulose, hydroxypropyl methylcellulose and the like (concentration: about 0.5-70% (W/V)), with a spraying powder containing an effective ingredient and additives (e.g. white sugar, cornstarch, crystalline cellulose, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidone and the like) to give granules.
  • a bonding agent such as white sugar, hydroxypropyl cellulose, hydroxypropyl methylcellulose and the like (concentration: about 0.5-70% (W/V)
  • an effective ingredient and additives e.g. white sugar, cornstar
  • the granules and fine granules are filled in capsules such as gelatin or hydroxypropyl methylcellulose and the like.
  • an effective ingredient is filled in capsules such as gelatin, hydroxypropyl methylcellulose and the like along with diluents (e.g. lactose, white sugar, glucose, starch, sucrose, microcrystalline cellulose, powdered licorice, mannitol, sodium bicarbonate, calcium phosphate, calcium sulfate and the like).
  • diluents e.g. lactose, white sugar, glucose, starch, sucrose, microcrystalline cellulose, powdered licorice, mannitol, sodium bicarbonate, calcium phosphate, calcium sulfate and the like.
  • the solid preparations can be coated by coating materials for masking, enteric coating, or sustained-release.
  • the coating materials are, for example, hydroxypropyl methylcellulose, ethyl cellulose, hydroxy methylcellulose, hydroxypropyl cellulose, polyoxyethylene glycol, tween 80, pluronic F68, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxy methylcellulose acetate succinate, eudragit (Rohm Co., Ltd., Germany, methacrylic acid.acrylic acid copolymers) and the like, but, if necessary, light screening agents such as titanium dioxide, red iron oxide and the like can be used.
  • FIG. 1 the layer structure of a cold formable laminate for manufacturing blister base parts shown in FIG. 5 , corresponding to the section line II-II in FIG. 5 ;
  • FIG. 2 the layered make-up of a lid film—that can be broken open by applying pressure—for the blister base parts according to FIG. 5 , along section line III-III in FIG. 5 ;
  • FIG. 3 the layered make-up of a peelable lid film for blister base parts
  • FIG. 4 plan view of a blister base part, made by cold forming the laminate of FIG. 1 ;
  • FIG. 5 section through the blister base part of FIG. 4 along line I-I;
  • FIG. 6 blister base part of FIG. 5 with sealed-on push through film of FIG. 2 or peelable lid film of FIG. 3 .
  • a cold formable laminate 10 for production of blister base parts for packaging a medicinal preparation capable of giving out smells exhibits, as shown in FIG. 1 , the following structure:
  • HDPE high density polyethylene
  • HDPE high density polyethylene
  • the oPA-film 12 forms the layer outer side of a blister made from laminate 10 ; the PE-layer 20 , 21 , 22 as sealing layer from the inner side.
  • a lid film 30 in the form of a push-through film for a blister made from the laminate 10 exhibits, as shown in FIG. 2 , the following layered structure:
  • the printing 38 with outer lacquer forms the—later—outer side of lid film 30
  • the hot-sealing lacquer or sealing coating 32 serves to seal the lid film 30 to the sealing layer 22 of a blister base part made from laminate 10 .
  • a lid film 50 in the form of a peelable film, for a blister base part made from laminate 10 exhibits, as shown in FIG. 3 , the following layered structure.
  • PET polyethylene-terephthalate
  • the printing 64 with outer lacquer layer 66 forms the—later—outer side of peelable lid film 50
  • the hot-sealing lacquer or sealing coating 52 serves to seal the lid film 50 to the PE layer 22 of a blister base part made from laminate 10 .
  • a blister base part 70 shown in FIG. 4 is made from the laminate 10 , whereby the cups 72 to accommodate e.g. tablets shape-formed in the laminate 10 by cold forming e.g. deep drawing using punch and mould.
  • a push-through lid film 30 or peelable lid film 50 is sealed onto the blister base part 70 to manufacture a blister pack 80 .
  • the blister base part and the blister pack described in the European patent application No. 05405383 can be preferably used for the present invention.
  • the inner layer of the blister base part is preferably made of polyolefin and contains as absorbent material preferably an oxide from the group of alkaline and alkaline earth metals. Calcium oxide (CaO) is especially preferred as absorbent material.
  • the preferred CaO content of the polyolefin inner layer is 0.5 to 50 wt. %, in particular 10 to 30 wt. % CaO.
  • the polyolefin of the inner layer is preferably a high density polyethylene (HDPE) and/or a linear low density polyethylene (LLDPE) and/or a low density polyethylene (LDPE) and/or polypropylene (PP). It may also contain components of acid-modified polyolefins such as ionomers e.g. Surlyn®, EAA or PP-MSA. These acid-modified polyolefins act as bonding agents so that in certain cases a separate primer can be dispensed with.
  • the polyolefin of the inner layer may be of one single layer or several layers.
  • a base part made from a laminate in which the polyolefin of the inner layer is a co-extruded layer of at least two layers, whereby the outermost layer, furthest removed from the aluminium foil, contains essentially no absorbent material.
  • the barrier layer is preferably an aluminium foil and is coated on the side facing the polyolefin with a bonding agent, in particular with a water-based or solvent-based primer, or with a polymeric bonding agent.
  • the innermost layer, lying next to the barrier layer, preferably contains essentially no absorbent material.
  • the particles of absorbent material can not be pressed into the aluminium foil serving as barrier layer. Consequently, no potentially weak points can be created in the aluminium foil and, thereby, also the pore-free formability is not reduced.
  • the outer layer is preferably a plastic film of oriented polyamide (oPA), oriented polypropylene (oPP) or oriented polyester, which is joined to the aluminium foil via an adhesive layer.
  • oPA oriented polyamide
  • oPP oriented polypropylene
  • polyester oriented polyester
  • the blister pack used in the present invention has a lid film which is sealed on to the inner side of the blister base part and features a barrier layer as barrier against water vapour and gases and a sealable inner layer on a first side on the barrier layer.
  • the polyolefin of the inner layer is preferably comprised of one single layer.
  • the sealable inner layer comprises a sealing medium in the form of a lacquer, in particular a hot-sealing lacquer, a film or a sealable coating and serves to seal the lid film to the inner side of the blister base part, whereby the sealing can be a permanent seal or a seal with lower bond strength in order to form a peelable opening.
  • the barrier layer is preferably an aluminium foil.
  • a blister base part is made from the laminate by way of cold forming. After filling the blister base part, a lid film containing a barrier layer against water vapour and gasses is sealed onto the inner side of the blister base part.
  • Formulation A was packed in the space of the blister package containing CaO described above (as shown in FIGS. 1 , 2 and 4 - 6 ).
  • Formulation A was packed in a space of a blister package without desiccant wherein a moisture impermeable packaging film is heat-sealed on a moisture impermeable seal material.
  • the medicinal package of the present invention remarkably reduced the concentration of biacetyl under the condition that is commonly used for a stability test of medicines, and maintained the deodorizing activities.
  • the present invention is useful to improve product's value of medicinal preparations capable of giving out smells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Packages (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
US12/311,252 2006-09-25 2007-09-21 Medicinal package Abandoned US20090308780A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/311,252 US20090308780A1 (en) 2006-09-25 2007-09-21 Medicinal package

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84673206P 2006-09-25 2006-09-25
PCT/JP2007/069129 WO2008041663A1 (fr) 2006-09-25 2007-09-21 Emballage médical
US12/311,252 US20090308780A1 (en) 2006-09-25 2007-09-21 Medicinal package

Publications (1)

Publication Number Publication Date
US20090308780A1 true US20090308780A1 (en) 2009-12-17

Family

ID=38792423

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/311,252 Abandoned US20090308780A1 (en) 2006-09-25 2007-09-21 Medicinal package
US13/340,000 Abandoned US20120100093A1 (en) 2006-09-25 2011-12-29 Medicinal package

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/340,000 Abandoned US20120100093A1 (en) 2006-09-25 2011-12-29 Medicinal package

Country Status (7)

Country Link
US (2) US20090308780A1 (fr)
EP (1) EP2068812B9 (fr)
JP (1) JP5340925B2 (fr)
AT (1) ATE552818T1 (fr)
CA (1) CA2664380C (fr)
ES (1) ES2381507T3 (fr)
WO (1) WO2008041663A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078812A3 (fr) * 2010-12-08 2012-10-18 Id-Con, Llc Systèmes et procédés de conditionnement
US20130153459A1 (en) * 2010-09-01 2013-06-20 Kyodo Printing Co., Ltd. Package
US20140158557A1 (en) * 2012-12-12 2014-06-12 Basf Corporation Gas Storage and Release Into Packaging After Filling
US10239680B2 (en) * 2010-09-01 2019-03-26 Kyodo Printing Co., Ltd. Blister package containing the laminated sheet and container

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5047156B2 (ja) * 2006-02-27 2012-10-10 武田薬品工業株式会社 医薬パッケージ
CH700645A2 (de) 2009-03-20 2010-09-30 Alcan Tech & Man Ltd Deckfolie als Durchdrückfolie für eine Blisterpackung.
TR200908847A2 (tr) 2009-11-23 2011-06-21 Bi̇lgi̇ç Mahmut Kuru toz formunda ilaç taşıyan blister ambalaj.
SI2612681T1 (sl) 2010-08-31 2019-05-31 Toray Industries, Inc. Obložno sredstvo za farmacevtsko trdno obliko, farmacevtska filmska formulacija in obložena farmacevtska trdna oblika
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
CN102970959B (zh) * 2012-03-01 2014-07-30 共同印刷株式会社 药品封装
WO2014080365A1 (fr) 2012-11-23 2014-05-30 Ranbaxy Laboratories Limited Procédé de réduction d'une odeur désagréable d'une composition pharmaceutique
JP6225490B2 (ja) * 2013-05-31 2017-11-08 大日本印刷株式会社 医薬品包装体
JP6664173B2 (ja) * 2014-09-09 2020-03-13 藤森工業株式会社 多層積層体及び包装体
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
IN201721047406A (fr) 2017-12-30 2020-06-19 Lupin Limited
AR118078A1 (es) 2019-02-27 2021-09-15 Dow Global Technologies Llc Composición para la eliminación de olores
US11912444B2 (en) 2019-06-03 2024-02-27 Amcor Flexibles Singen Gmbh Process for the conditioned packaging of hard gelatin capsules
US20240000662A1 (en) * 2022-06-29 2024-01-04 Cryoport, Inc. Cassette bags for transporting biomaterials

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243054A (en) * 1991-06-27 1993-09-07 Takeda Chemical Industries, Ltd. Compound which is angiotensin ii antagonist
US20050187269A1 (en) * 2004-02-25 2005-08-25 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
US20090054502A1 (en) * 2005-03-30 2009-02-26 Takeda Pharmaceutical Company Limited Benzimidazole Derivative and Use as Angiotensin II Antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0624571B2 (ja) * 1988-11-21 1994-04-06 明治製菓株式会社 医薬品包装容器
JPH0471560A (ja) * 1990-07-10 1992-03-06 Mect Corp 包装体
JP3015677B2 (ja) * 1994-08-10 2000-03-06 ファイザー製薬株式会社 フィルムコーティングを施した分割錠剤
US20040131805A1 (en) * 2002-06-20 2004-07-08 Merical Rick L. Films having a desiccant material incorporated therein and methods of use and manufacture
JP4659523B2 (ja) * 2005-04-26 2011-03-30 共同印刷株式会社 ブリスター用フィルム及びブリスター用包装容器
WO2007097452A1 (fr) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited Emballage-coque à usage médical

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243054A (en) * 1991-06-27 1993-09-07 Takeda Chemical Industries, Ltd. Compound which is angiotensin ii antagonist
US20050187269A1 (en) * 2004-02-25 2005-08-25 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20060281795A1 (en) * 2004-02-25 2006-12-14 Takanobu Kuroita Benzinidazole Derivative and Use As AII Receptor Antagonist
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20090054502A1 (en) * 2005-03-30 2009-02-26 Takeda Pharmaceutical Company Limited Benzimidazole Derivative and Use as Angiotensin II Antagonist
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130153459A1 (en) * 2010-09-01 2013-06-20 Kyodo Printing Co., Ltd. Package
US10239680B2 (en) * 2010-09-01 2019-03-26 Kyodo Printing Co., Ltd. Blister package containing the laminated sheet and container
WO2012078812A3 (fr) * 2010-12-08 2012-10-18 Id-Con, Llc Systèmes et procédés de conditionnement
US20140158557A1 (en) * 2012-12-12 2014-06-12 Basf Corporation Gas Storage and Release Into Packaging After Filling

Also Published As

Publication number Publication date
ES2381507T3 (es) 2012-05-28
EP2068812A1 (fr) 2009-06-17
CA2664380C (fr) 2016-08-23
EP2068812B1 (fr) 2012-04-11
ATE552818T1 (de) 2012-04-15
US20120100093A1 (en) 2012-04-26
JP2010504252A (ja) 2010-02-12
EP2068812B9 (fr) 2012-08-08
WO2008041663A1 (fr) 2008-04-10
JP5340925B2 (ja) 2013-11-13
CA2664380A1 (fr) 2008-04-10

Similar Documents

Publication Publication Date Title
EP2068812B9 (fr) Emballage médical
TWI402085B (zh) 包裝材、壓泡包裝及錠劑
JP5936542B2 (ja) 包装体
RU2448026C2 (ru) Упаковка, содержащая фармацевтические лекарственные формы
JP6175425B2 (ja) Ｐｔｐ又はブリスターパック用積層体及びｐｔｐ又はブリスターパック
EP1835897A2 (fr) Emballage impermeable a l'oxygene facultativement dote d'un desoxygenant, compositions d'hormones thyroidiennes stabilisees et procedes de stockage de ces compositions pharmaceutiques
US20210015776A1 (en) Methods of stabilization of levothyroxine sodium tablets
JP2014139256A (ja) 包装により安定保存された固形製剤
WO2007097452A1 (fr) Emballage-coque à usage médical
EP2127628A1 (fr) Emballage de dose d'unité
JP2019043880A (ja) 医薬組成物
JP6927663B2 (ja) 固形製剤包装体、及び固形製剤の臭い除去方法
KR20200121480A (ko) 빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NONOMURA, KOJI;REEL/FRAME:022499/0038

Effective date: 20090219

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION